Skip to main content
. 2020 Sep 28;38(34):4042–4054. doi: 10.1200/JCO.20.00948

FIG 1.

FIG 1.

Kaplan-Meier assessments of (A) progression-free survival (PFS) and (B) overall survival (OS). BR, bendamustine plus rituximab; EOCT, end of combination therapy; EOT, end of treatment; HR, hazard ratio; ITT, intent-to-treat; VenR, venetoclax plus rituximab.